Fig. 2From: Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trialsProgression-free survival of patients with advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma treated with Zolbetuximab plus chemotherapy versus chemotherapy aloneBack to article page